GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Rating of “Moderate Buy” from Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $133.1111.

Several research firms have commented on WGS. Piper Sandler upped their price objective on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Wells Fargo & Company raised their target price on shares of GeneDx from $95.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 4th. BTIG Research upped their price target on shares of GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research note on Friday. Guggenheim reissued a “buy” rating and issued a $170.00 price target (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Finally, Zacks Research cut GeneDx from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 2nd.

GeneDx Trading Down 2.5%

GeneDx stock opened at $151.51 on Monday. The stock has a 50-day simple moving average of $139.26 and a 200 day simple moving average of $114.15. The stock has a market capitalization of $4.38 billion, a P/E ratio of 1,683.44 and a beta of 1.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71. GeneDx has a 52 week low of $55.17 and a 52 week high of $170.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. The company had revenue of $116.74 million during the quarter, compared to analysts’ expectations of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. Analysts expect that GeneDx will post 0.97 earnings per share for the current year.

Insider Activity at GeneDx

In other news, CEO Katherine Stueland sold 3,639 shares of GeneDx stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $159.28, for a total transaction of $579,619.92. Following the completion of the sale, the chief executive officer owned 6,344 shares of the company’s stock, valued at approximately $1,010,472.32. This trade represents a 36.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joshua Ruch sold 38,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the completion of the sale, the director directly owned 11,941 shares of the company’s stock, valued at approximately $1,914,978.17. The trade was a 76.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 59,680 shares of company stock worth $8,951,356 in the last ninety days. 29.60% of the stock is owned by company insiders.

Institutional Trading of GeneDx

A number of institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after purchasing an additional 181 shares during the period. Jones Financial Companies Lllp lifted its position in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the period. Quarry LP grew its stake in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares in the last quarter. Chung Wu Investment Group LLC increased its holdings in GeneDx by 8.2% in the 2nd quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock valued at $305,000 after buying an additional 250 shares during the period. Finally, Kovack Advisors Inc. increased its holdings in GeneDx by 14.3% in the 3rd quarter. Kovack Advisors Inc. now owns 2,868 shares of the company’s stock valued at $309,000 after buying an additional 358 shares during the period. 61.72% of the stock is currently owned by institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.